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Summary
The small GTPase Arf6 has been shown to regulate the
post-endocytic trafficking of a subset of membrane
proteins, including b1 integrins, and inhibition of Arf6
function impairs both cell adhesion and motility [1].
The activity of Arf GTPases is regulated by a large fam-
ily of guanine nucleotide exchange factors (GEFs) [2].
Arf-GEP100/BRAG2 is a GEF with reported specificity
for Arf6 in vitro [3], but it is otherwise poorly character-
ized. Here we report that BRAG2 exists in two ubiqui-
tously expressed isoforms, which we call BRAG2a
and BRAG2b, both of which can activate Arf6 in vivo.
Depletion of endogenous BRAG2 by siRNA leads to
dramatic effects in the cell periphery; one such effect
is an accumulation of b1 integrin on the cell surface
and a corresponding enhancement of cell attachment
and spreading on fibronectin-coated substrates. In
contrast, depletion of Arf6 leads to intracellular accu-
mulation of b1 integrin and reduced adhesion and
spreading. These findings suggest that Arf6 regulates
both endocytosis and recycling of b1 integrins and
that BRAG2 functions selectively to activate Arf6 dur-
ing integrin internalization.
Results
Multiple BRAG2 Splice Isoforms
There are currently 15 recognized Arf GEFs in the human
genome, and these can be divided into five subfamilies
[2]. The previously described Arf-GEP100 [3] belongs
to a new subfamily referred to as the Brefeldin-Resistant
Arf GEFs (BRAGs). In this nomenclature, Arf-GEP100 is
called BRAG2. We found that immunoprecipitation of
Hela cell lysates with a polyclonal BRAG2 antibody
yielded two bands, one of 150 kDa and one of 120 kDa
(Figure 1A). Database analysis revealed that BRAG2
may exist in as many as four splice isoforms, one of
which encodes a larger product with an N-terminal ex-
tension of 122 amino acids (Figure 1B; also Figure S1
in the Supplemental Data available with this article
*Correspondence: jec9e@virginia.eduonline). We were able to amplify a PCR product from
HEK293 cell mRNA corresponding to this longer iso-
form, which we call BRAG2b. When expressed in Hela
cells, this longer isoform comigrated with the 150 kDa
endogenous protein, whereas Arf-GEP100 (which we
now call BRAG2a) comigrated with the 120 kDa band
(data not shown). Both proteins were depleted by
siRNA-mediated knockdown with an siRNA duplex cor-
responding to a region shared by both isoforms, thus
confirming that these proteins represent endogenous
BRAG2a and BRAG2b (Figure 1A). Both isoforms were
also detected in a wide variety of other cell lines, sug-
gesting that they are ubiquitously expressed.
Like other Arf GEFs, BRAG2 is expressed at low levels
in most cells. We were unable to detect endogenous
BRAG2 by immunofluorescene microscopy in any ex-
amined cell type, including HEK293, MDCK, A431,
BHK, PC12, and Hela cells (data not shown). Therefore,
to determine if BRAG2a and BRAG2b are differentially
localized, we examined the distribution of epitope-
tagged constructs by immunofluorescence microscopy.
Surprisingly, we found that both BRAG2a and BRAG2b
exhibited a pronounced accumulation in the nucleus in
most cell types (Figure S2), although a cytosolic pool
was readily apparent, especially for BRAG2b. Both iso-
forms were exclusively nuclear after treatment of cells
with leptomycin B (Figure S2), which blocks the Crm1/
exportin1 nuclear-export machinery, suggesting that
these proteins cycle between the nucleus and the cyto-
plasm. Results of a recent nuclear proteomics analysis
also confirm the presence of endogenous BRAG2 in
Hela cell nuclei [4]. However, immunoprecipitation of en-
dogenous BRAG2 from cytosolic and nuclear fractions
of Hela cells revealed that approximately 90% of each
isoform is cytosolic at steady state (Figure S2I). It is pos-
sible that the nuclear pool appears more prominent by
immunofluorescence microscopy because it is concen-
trated into a smaller volume than the diffuse cytosolic
pool, even at low levels of expression.
BRAG2 Isoforms Have In Vivo ARF6 GEF Activity
Previous data indicated that, although BRAG2a ex-
hibited some activity toward Arf1 and Arf5 in vitro, it ap-
peared to prefer Arf6 as a substrate [3]. To evaluate
BRAG2 activity in vivo, we used a pull-down assay in
which Arf-GTP is recovered from cell lysates based on
its affinity for the Arf binding domain of the effector
protein GGA3 [5]. HeLa cells were transfected with
constructs encoding either BRAG2a or BRAG2b, and
Arf6-GTP was precipitated by the use of GST-GGA3 as
previously described. In agreement with the previously
reported in vitro data, expression of exogenous BRAG2a
or BRAG2b resulted in increased levels of Arf6-GTP (Fig-
ure 1C). As expected, the GEF activity of BRAG2 was
dependent upon the Sec7 catalytic domain and could
be disrupted by a point mutation substituting the con-
served catalytic glutamate residue with lysine (BRA-
G2aE498K). Importantly, the Arf-GEF activity of BRAG2a
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an N-terminal HA tag or a C-terminal GFP tag (Figure 1C).
Furthermore, in keeping with their role as Arf6 GEFs, we
found that ectopic expression of either BRAG2a or
BRAG2b resulted in actin-cytoskeleton alterations, in-
cluding disruption of stress fibers and changes in cell
shape (Figure S3). Finally, as we have previously shown
for another Arf6 GEF, ARNO [6], treatment of cells with
phorbol esters led to recruitment of both BRAG2a and
BRAG2b to the cell cortex and enhanced their effects
on the actin cytoskeleton (Figure S3).
A Role for BRAG2 in Cell Adhesion
Arf6 has been reported to mediate the recycling of integ-
rins from an endosomal compartment to the plasma
membrane [1], and expression of dominant-negative
Arf6 impairs both cell spreading [7] and cell migration
[8, 1, 5, 9]. To determine if BRAG2 regulates Arf6 activa-
tion in the context of cell adhesion, we measured attach-
ment and spreading in cells where BRAG2 expression
was reduced by using RNAi. As described above, we
Figure 1. BRAG2 Exists in Two Isoforms that Each Activate ARF6
In Vivo
(A) Hela cells were either mock-transfected (M) or tranfected for
48 hr with scrambled siRNA duplex (C) or a specific duplex targeting
a sequence shared by both isoforms (B). Endogenous BRAG2
was then concentrated by immunoprecipitation and detected by
immunoblotting with the same antibody. Lysates were probed with
a-tubulin antibody to demonstrate equal protein levels in each
sample.
(B) Domain organization of BRAG2a and BRAG2b. The two isoforms
share a putative calmodulin binding IQ domain (IQ), three proline-
rich domains (PRD), three predicted nuclear-localization signals
(NLS), the catalytic Arf-GEF domain (sec7), a pleckstrin homology
domain (PH), and a coiled-coil domain (CC).
(C) Both BRAG2 isoforms exhibit ARF6 GEF activity in vivo. HeLa
cells were cotransfected with HA-ARF6 and one of the following:
empty vector (mock), HA-BRAG2a (a), HA-BRAG2b (b), BRAG2a-
GFP, or one of the catalytically inactive mutants HA-BRAG2aE498K
and BRAG2aE498K-GFP (aEK). GTP bound Arfs were precipitated
from cell lysates by a pull-down assay with GST-GGA3 as previously
described [5] and probed for Arf6 with antibody to the HA tag. Ex-
pression levels of the various BRAG2 constructs, total HA-ARF6,
and endogenous a-tubulin in total cell lysates are shown.reduced expression of both BRAG2a and BRAG2b by
using a single siRNA duplex corresponding to a se-
quence shared by both isoforms (see Experimental
Procedures). Expression of both BRAG2a and BRAG2b
was typically reduced by 85% under these conditions
(Figure 2A).
To determine if knockdown of BRAG2 altered cell ad-
hesion, we measured the binding of cells to immobilized
fibronectin in a dose-response assay. Equivalent num-
bers of cells were plated onto microtiter wells coated
with fibronectin at concentrations ranging from 0–10
ug/ml. To our surprise, we found that cells in which
BRAG2 was depleted actually bound fibronectin more
efficiently than control cells, especially at moderate fi-
bronectin concentrations (Figure 2B). Interestingly, this
effect was specific for BRAG2; knockdown of ARNO,
which is also expressed in Hela cells and can also acti-
vate Arf6, had no detectable effect on cell adhesion.
Similarly, we found that cells in which BRAG2 was
knocked down spread more rapidly than controls on
fibronectin-coated substrates (Figures 3A and 3C).
Quantitative analysis of cells attached for 30 min indi-
cated that the mean area of the BRAG2 knockdowns
was more than twice that of control cells and that the
range of cell diameters was clearly broader (Figures
3B and 3D).
These observations suggested that reduced BRAG2
expression leads to either increased levels of integrins
on the cell surface or enhanced activation of existing
surface integrins. Because the primary fibronectin bind-
ing integrin in Hela cells is a5b1, we quantitated the sur-
face expression of the endogenous b1 integrin subunit
(CD29) by flow cytometry by using a pan-b1 monoclonal
antibody (MEM101A) that is not sensitive to conforma-
tion or ligand binding. Over four separate experiments,
knockdown of BRAG2 resulted in an average 51%
(6 6.8%) increase in surface levels of b1 relative to con-
trols (Figure 4B). Immunoblotting of cell lysates demon-
strated that overall expression of the b1 subunit was
unaffected by BRAG2 knockdown (data not shown),
indicating that the observed changes resulted from re-
distribution of the integrin from an intracellular pool to
the cell surface. Taken together, these data indicate
that BRAG2 regulates the trafficking of b1 integrins
and that this can have a quantitatively significant impact
on cell attachment and spreading.
Knockdown of Arf6 Reduces Surface Integrin Levels
and Inhibits Cell Spreading
Because BRAG2 is an activator of Arf6, BRAG2 knock-
down should result in reduced levels of Arf6-GTP at
the plasma membrane. In principle, expression of dom-
inant-negative Arf6 should have a similar effect, by bind-
ing and sequestering endogenous GEFs. However, as
described above, the dominant-negative Arf6 mutant
Arf6T27N has previously been shown to inhibit integrin
recycling [1], cell spreading [7], and migration [5], ex-
actly the opposite of what we observed when BRAG2
levels were reduced. However, the interpretation of ex-
periments utilizing dominant-negative Arf6 constructs
may be complicated by Arf6T27N sequestering GEFs
that normally activate other Arfs, or by binding to other
non-GEF proteins that may alter cell attachment. To cir-
cumvent this problem, we used RNAi to knock down
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317Figure 2. Knockdown of BRAG2 Enhances Binding of Cells to Fibronectin
(A) Knockdown of BRAG2 or ARNO by RNAi. HeLa cells were treated for 48 hr with RNA duplexes, and knockdown was confirmed by immuno-
precipitation followed by immunoblotting. Endogenous ARNO runs immediately below the IgG heavy chain on SDS PAGE gels.
(B) Cell binding to fibronectin. HeLa cells transfected with scrambled (triangle), ARNO (diamond), or BRAG2 (square) RNA duplexes were plated
onto 96-well plates coated with fibronectin concentrations ranging from 0 to 10 mg/ml, and adherent cells were then quantitated as described in
the Experimental Procedures. Error bars indicate the mean 6 SE for triplicate determinations.expression of endogenous Arf6. This knockdown was
selective because Arf6 expression was typically re-
duced by more than 80%, whereas expression of en-
dogenous Arf1 was not detectably altered (Figure 4A).Intriguingly, analysis of these cells by flow cytometry re-
vealed that surface expression of b1 integrin was re-
duced by 34% (6 5.9%, n = 4), in contrast to the elevated
surface levels in cells where BRAG2 was knocked downFigure 3. Depletion of BRAG2 Enhances Cell Spreading on Fibronectin-Coated Substrates
HeLa cells treated with either control siRNA duplexes (A and B) or BRAG2-specific duplexes (C and D) were harvested nonenzymatically and
replated onto fibronectin-coated coverslips for 15 min as described in the Experimental Procedures. Cells were then fixed and stained for fila-
mentous actin (A and C). For each condition, the area of 300 individual cells was quantitated with ImageJ software, and the distributions are
shown in (B) and (D).
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318Figure 4. Depletion of BRAG2 and Arf6 Have Opposing Effects on Cell-Surface Expression of b1 Integrin but Not Transferrin Receptor
(A) Selective depletion of Arf6 by RNAi. Hela cells were treated with either scrambled oligonucleotide (con) or Arf6-specific siRNA duplex (KD).
Lysates were then probed with antibodies specific for endogenous Arf6 or Arf1.
(B) FACS analysis of surface b1 integrin expression. HeLa cells were transfected with RNA duplexes as indicated and harvested 48 hr later as
described in Figure 2. Cells were then incubated with PE-conjugated anti-b1 integrin antibody MEM101A and analyzed by flow cytometry. Values
are normalized to the mean fluorescence intensity of control cells. Error bars indicate the mean 6 SE of four independent determinations.
(C) Cells transfected with control RNA duplex (blue) or Arf6-specific duplex (red) were harvested and replated on fibronectin-coated coverslips as
described in Figure 3. Cell areas were quantitated 60 min after replating.
(D) Cells were treated as in (B) but were labeled with PE-conjugated anti-transferrin receptor antibody (CD71). Error bars indicate the mean6 SE
of four independent determinations.(Figure 4B). As described above for the BRAG2 knock-
down, total b1 expression was unchanged under these
conditions, suggesting that b1 integrins were seques-
tered inside the cell. In agreement with this observation,
we found that cells expressing reduced levels of Arf6
spread less efficiently on fibronectin-coated substrates
(Figure 4C). Finally, no change in the level of surface
transferrin receptor was observed under these condi-
tions (Figure 4D), indicating that the effects of either
BRAG2 or Arf6 depletion are cargo specific. Taken to-
gether with the results described above, these findings
suggest that Arf6 functions at multiple sites in the endo-
cytic/recycling system and that BRAG2 selectively reg-
ulates Arf6 activation in the endocytic process.
Discussion
Previous work has shown that b1 integrins internalized
from the cell surface enter an endosomal compartment
that is enriched for Arf6 [1, 10]. In addition, expression
of dominant inhibitory Arf6 mutants impairs recycling of
this endosomal integrin pool to the plasma membrane,
suggesting that Arf6 activation is necessary for integrin
recycling [1]. Here we show that siRNA-mediated knock-
down of Arf6 has a similar effect in that it reduces sur-
face expression of b1 integrins and inhibits both cell
attachment and spreading on fibronectin-coated sub-
strates. Because overall levels of b1 were unchanged
under these conditions, we interpret these results to
indicate that depletion of Arf6 impairs b1 recycling.In contrast, although our experiments clearly demon-
strate that BRAG2 potently activates Arf6 in vivo, we
found that depletion of endogenous BRAG2 leads to
accumulation of b1 integrin at the cell surface, and this
accumulation results in more efficient binding of cells
to fibronectin and an increased rate of spreading. This
observation suggests that internalization of b1 integrins
is mediated, at least in part, by BRAG2, through its acti-
vation of Arf6 at the plasma membrane.
Why does depletion of BRAG2 have the opposite ef-
fect from depletion of Arf6 itself? In the secretory path-
way, Arf1 is thought to function at multiple locations to
generate different classes of carrier vesicles, and accu-
mulating evidence indicates that different Arf1 GEFs
control its activation at each site [11–16]. It is likely
that a similar scenario exists for Arf6 in the endocytic
pathway, with one subset of GEFs functioning at the
plasma membrane and another on the surface of endo-
somes. Thus, knockdown of a specific Arf6 GEF would
impair only the transport step(s) mediated by that GEF,
rather than all steps along the pathway that are Arf6-de-
pendent. The intracellular accumulation of b1 integrin af-
ter Arf6 depletion may reflect a more rigid requirement
for Arf6 in recycling than in endocytosis. Although other
GEFs presumably activate Arf6 on the surface of endo-
somes to promote recycling, their identity remains un-
known. Because the PH domains of EFA6 and ARNO/cy-
tohesin subfamily members preferentially bind PI(4,5)P2
and PI(3,4,5)P3, respectively, it seems likely that these
GEFs function primarily at the plasma membrane, which
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study that knockdown of ARNO did not affect cell adhe-
sion supports this hypothesis. However, other BRAG
subfamily members, such as BRAG1 or BRAG3, which
are relatively uncharacterized, remain possibilities.
How does Arf6 regulate integrin internalization? Sur-
prisingly little is known about the mechanisms by which
integrins are internalized. Both avb5 [17] and a5b1 integ-
rins [18, 19] have been reported to localize at least par-
tially in clathrin-coated pits, and avb5 endocytoses
bound vitronectin in a clathrin-dependent manner [17].
Arf6-mediated activation of phosphatidlyinositol 4-P 5-
kinase (PIP5K) isoforms has been shown to promote
the assembly of clathrin and the AP-2 adaptor complex
onto the plasma membrane [20, 21]. Moreover, bacterial
pathogens of the genus Yersinia are internalized via their
interaction with b1 integrins, and recent evidence indi-
cates that bacterial uptake requires the recruitment
and activation of PIP5K-a by Arf6 [22]. Whether Arf6
also regulates integrin internalization via its activation
of PIP5K remains to be determined.
It will also be interesting to determine if BRAG2 and
Arf6 regulate the internalization of other molecules at
the cell surface. For example, the Drosophila BRAG2 or-
tholog, Schizo, has been reported to regulate neuronal
pathfinding in the developing central nervous system
by controlling the surface levels of the repulsive ligand
Slit on midline glial cells [23]. Because the Slit/Robo sig-
naling pathway is conserved in mammals [24], BRAG2
may play a similar role in mammalian development.
Conclusions
The number of GEFs (15) and GAPs (17) that control Arf
activation far exceeds the number of Arfs themselves,
and a major challenge in this field has been to assign
specific cellular functions to each of these regulatory
molecules. Among the Arf GEFs, the BRAGs have been
relatively uncharacterized. Here we show that BRAG2
exists in two ubiquitously expressed isoforms that both
activate Arf6 in vivo. These proteins appear to function
primarily in the cell periphery, where they regulate the
surface level of b1 integrins and, consequently, cell ad-
hesion. The specific mechanisms by which Arf6 may
regulate integrin endocytosis remain to be explored.
Experimental Procedures
DNA Constructs
BRAG2a (KIAA0763) cDNA was obtained from the Kasuza DNA Re-
search Institute and subcloned into EcoRI/NotI sites of pRC-HA.
This vector was used as a template for site directed PCR mutagen-
esis to produce catalytically inactive BRAG2a (E498K). cDNA encod-
ing the extended N terminus of BRAG2b was amplified by RT-PCR
from HEK293 mRNA with the following primers: 50-GCCGCCAT
GTGGTGCCTGC-30 and 50-CTGGCGAAACGCCGTCTGGATGG-30.
This cDNA was subcloned into the pRC-HA-BRAG2a vector to
produce pRC-HA-BRAG2b. BRAG2a-GFP was subcloned into the
HindIII/BamHI sites of pRK7.
Cell Culture and Transfections
HeLa cells were maintained in complete DME (10% FBS) with antibi-
otics at 37ºC and with 5% CO2. Cells were transfected with DNA
plasmids via Fugene6 as recommended by the manufacturer
(Roche). For RNAi, approximately 117 nM final concentration of
siRNA duplex was delivered to cells by the use of 10 ml Oligofect-
amine (Invitrogen)/35 mm dish in a total volume of about 1.7 ml.
The BRAG2 siRNA duplex corresponded to the sequence 50-AGAACUCGGUGACGUACAG-30 and was obtained from Dharmacon. The
control duplex (50-UCGACUGUGGAUUGGCAUU-30) was obtained
from Ian Macara (The University of Virginia).
Immunofluorescence and Image Analysis
Cells were grown on glass coverslips and fixed with 4% paraformal-
dehyde 48 hr after transfection. Images were acquired with a Nikon
Eclipse E800 microscope equipped with a RETIGA digital camera
(Q-Imaging) and with Adobe Photoshop software.
Immunoprecipitation and Immunoblotting
Polyclonal rabbit anti-BRAG2 antibody, raised against residues
153–176 of BRAG2a as described previously [3], was obtained
from Vladimir Marshansky (Massachusetts General Hospital) and
used for immunoprecipitation at 1/500 dilution. At least 1.8 mg of to-
tal HeLa cell protein was required to detect BRAG2 isoforms
by immunoprecipitation. Immunoprecipitation and immunoblotting
were performed as described by Hansen and Casanova [25]. For
immunoblotting, a 1/1000 dilution of rabbit anti-BRAG2, a 1/500
dilution of mouse anti-Arf6 (8A6-2 from Sylvain Bourgoin, CHUL re-
search center, Quebec), and a 1/2000 dilution of polyclonal anti-Arf1
and 1/10,000 of mouse anti-a-tubulin (DM1A Sigma) were used.
Cell-Adhesion Assays
Triplicate wells of microtiter plates were coated with fibronectin in
concentrations ranging from 0.1 to 10 mg/ml, and nonspecific bind-
ing sites blocked with 10 mg/ml heat-denatured BSA for 1 hr. HeLa
cells were harvested nonenzymatically by incubation in PBS con-
taining 4 mM EDTA and 4 mM EGTA, washed in serum-free
DMEM, and aliquoted into wells for 15 min at 53 105 cells/well. After
removal of nonadherent cells by washing, remaining cells were fixed
in 4% paraformaldehyde and incubated with 1% crystal violet for
15 min. After extensive washing, the dye was extracted with 1%
deoxycholate, and the OD595 was quantitated in a microplate reader.
For spreading assays, cells were harvested as above and replated
onto glass coverslips coated with 10 mg/ml fibronectin for 15 min
or 30 min at 37ºC. Cells were then fixed and permeablized, and ran-
dom fields of cells were imaged with a 203 phase-contrast objective
lens. The diameters of 300 cells per condition were measured with
Image J software (NIH), and the diameters were sorted into bins
with Excel.
Flow Cytometry
Cells were harvested as described above and washed in PBS con-
taining 0.2% BSA, and 13 105 cells per sample were stained without
fixation at 4ºC. For detection of surface b1 integrin, PE-conjugated
anti-CD29 IgG (Caltag) was used at 1:400. Nonspecific labeling
was determined with a PE-labeled isotype control antibody. After
samples were fixed in 4% paraformaldehyde, the mean fluores-
cence intensity of each sample was quantitated with a Becton Dick-
inson FACScalibur desktop analyzer.
Supplemental Data
Supplemental Data include three figures and are available with this
article online at http://www.current-biology.com/cgi/content/full/
16/3/315/DC1/.
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